BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP George Eric Davis sold 30,000 shares of the firm’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $90.66, for a total value of $2,719,800.00. Following the transaction, the executive vice president now owns 112,942 shares in the company, valued at $10,239,321.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
George Eric Davis also recently made the following trade(s):
- On Thursday, November 30th, George Eric Davis sold 1,200 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $85.64, for a total value of $102,768.00.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) traded down $3.41 during trading on Monday, hitting $87.41. The stock had a trading volume of 2,174,962 shares, compared to its average volume of 1,190,000. The company has a quick ratio of 3.81, a current ratio of 4.91 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $15,350.00, a price-to-earnings ratio of -105.31 and a beta of 1.71. BioMarin Pharmaceutical Inc. has a twelve month low of $80.10 and a twelve month high of $100.51.
BMRN has been the topic of several recent research reports. Stifel Nicolaus cut their target price on BioMarin Pharmaceutical from $107.00 to $105.00 and set a “buy” rating on the stock in a report on Friday, October 27th. BidaskClub lowered BioMarin Pharmaceutical from a “sell” rating to a “strong sell” rating in a report on Saturday, January 20th. BMO Capital Markets restated a “buy” rating and set a $117.00 target price on shares of BioMarin Pharmaceutical in a report on Friday, October 20th. JPMorgan Chase & Co. set a $130.00 target price on BioMarin Pharmaceutical and gave the company a “buy” rating in a report on Sunday, October 29th. Finally, Credit Suisse Group restated an “outperform” rating and set a $124.00 target price (up from $114.00) on shares of BioMarin Pharmaceutical in a report on Thursday, October 19th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $111.60.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.